Home|Journals|Articles by Year Follow on Twitter

Directory for Medical Articles
 

Open Access

Original Research



Pharmacovigilance study of adverse cutaneous drug reactions in a tertiary care hospital

Tejas Acharya, Dimple Mehta, Hiral Shah, Jayendra Dave.

Cited by (2)

Abstract
Background: The wide and indiscriminate use of drugs has increased the incidence and the modes of presentation of cutaneous drug reaction. Adverse cutaneous drug reactions are common, comprehensive information about their incidence, severity and ultimate health effects are unavailable.

Objective: To study and evaluate incidence of adverse cutaneous drug reaction (ACDR) at our tertiary care hospital and assess the impact of active surveillance on adverse drug reaction (ADR) reporting.

Materials and Methods: Prospective study involving 29,156 patients was carried out by active observation of patients attending Dermatology department over a period of 21 months. Retrospective study involving 61000 patients attended Dermatology OPD over last 4 years was carried by available data of dermatology department. Both the studies were compared by chi square test.

Results: In prospective study 48 (0.17%) were diagnosed as having ACDR. Acneform eruption (25%) followed by fixed drug eruption (FDE) (22.92%) were the most common morphological forms. The most common drugs responsible were betamethasone, isoniazid and rifampicin for acneform eruption, while metronidazole and paracetamol for FDE. WHO causality assessment showed 13 were certain, 24 were probable and 11 were possible in nature. Hartwig severity assessment revealed 40 were moderate, 07 were mild and 01 was severe. Modified Schomock and Thronton scale showed 37.5% were definitely preventable, 33.33% were probably preventable and 29.17% were not preventable. In retrospective study 63 (0.10%) ACDRs were reported, out of them FDE was most common (28.57%), followed by acneform eruption (11.11%). Antimalarials and metronidazole were most commonly responsible for FDE while systemic steroids were responsible for acneform eruption. There is significant association between both the studies with higher incidence in prospective study (p

Key words: Adverse cutaneous drug reaction (ACDR); Pharmacovigilance; Causality of adverse drug reactions (ADR); Severity of ADR; Preventability of ADR.



Similar Articles

Synthesis of enhanced corrosion resistant Fe-B-C-Ti amorphous ribbons and evaluation of their photodegradation efficiency under light irradiation.
Zuo M, Moztahida M, Lee DS, Yi S
Chemosphere. 2022; 287(Pt 2): 132175

Sensitive detection of trace 4-methylimidazole utilizing a derivatization reaction-based ratiometric surface-enhanced Raman scattering platform.
Gou L, Zeng X, Du H, Li L, Tian Y, Hou X, Wu L
Talanta. 2022; 237(): 122925

Hydrophobic and thermal-insulating aerogels based on rigid cellulose nanocrystal and elastic rubber.
Chen Z, Li Z, Lan P, Xu H, Lin N
Carbohydrate polymers. 2022; 275(): 118708

An environment-friendly dip-catalyst with xylan-based catalytic paper coatings.
He M, Song T, Qi H, Xiang Z
Carbohydrate polymers. 2022; 275(): 118707

Drug-drug interaction between cannabidiol and phenobarbital in healthy dogs.
Doran CE, McGrath S, Bartner LR, Thomas B, Cribb AE, Gustafson DL
American journal of veterinary research. 2022; (): 1-9


Full-text options


Latest Statistics about COVID-19
• pubstat.org


Add your Article(s) to Indexes
• citeindex.org






Covid-19 Trends and Statistics
ScopeMed.com
CiteIndex.org
CancerLine
FoodsLine
PhytoMedline
Follow ScopeMed on Twitter
Author Tools
eJPort Journal Hosting
About BiblioMed
License Information
Terms & Conditions
Privacy Policy
Contact Us

The articles in Bibliomed are open access articles licensed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License (https://creativecommons.org/licenses/by-nc-sa/4.0/) which permits unrestricted, non-commercial use, distribution and reproduction in any medium, provided the work is properly cited.
ScopeMed is a Database Service for Scientific Publications. Copyright ScopeMed Information Services.



ScopeMed Web Sites